HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on Tyra Biosciences (NASDAQ:TYRA) and raises the price target from $17 to $20.
August 11, 2023 | 11:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a 'Buy' rating on Tyra Biosciences and raises the price target from $17 to $20.
The news is directly related to Tyra Biosciences. The 'Buy' rating maintained by HC Wainwright & Co. and the increase in price target from $17 to $20 indicates a positive outlook for the company. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100